Professional profile
About Ying
Equity Partner | Private equity & investment funds; capital markets; bankruptcy, insolvency & reorganization; life sciences
Ying Ye is an equity partner in Zhong Lun Law Firm's Wuhan office whose practice focuses on private equity and investment funds, Chinese mainland capital markets, and bankruptcy, insolvency and reorganization. Her public profile also identifies a strong industry focus on pharmaceuticals and life sciences, making her particularly relevant to Wuhan's biotechnology, healthcare and venture-investment ecosystem.
Read full profile
Ye has more than seventeen years of legal practice according to Zhong Lun's profile. She has long advised listed companies, public companies, state-owned financial investment platforms, government bodies and investment institutions. Her representative matters show work across fund formation, portfolio investment, corporate M&A and liquidation or reorganization. This breadth is important because life-sciences investments often have long time horizons and uncertain exit paths.
Her private-fund experience includes work for major Hubei and Wuhan investment platforms and large industry funds. Public matters involve cooperation among local funds, major financial institutions and well-known investment firms to establish large RMB funds. She has also advised on fund investments into biotechnology, medical and advanced technology companies. This gives her profile substantial relevance to institutional investors rather than only startup-side financing.
The life-sciences sector creates distinctive legal problems for funds. A biotech company may require years of financing before product commercialization. Regulatory approval can fail, clinical timelines can slip and later financing may be unavailable. When a portfolio company becomes distressed, the fund must decide whether to provide bridge capital, sell the asset, enforce investor rights, restructure the company or allow insolvency proceedings.
Ye's bankruptcy and reorganization practice provides a useful connection to these downside scenarios. Her representative matters include liquidation and dissolution projects, including a Sino-foreign joint venture. For a PE fund, the legal analysis of a distressed portfolio company should begin before formal bankruptcy. Investor rights, shareholder loans, security, intellectual property, employee obligations and creditor priority all affect recovery.
Her capital-markets experience creates the opposite side of the investment lifecycle: successful exits and public-market transactions. A life-sciences fund may invest with an IPO strategy but later need to switch to M&A, secondary transfer or restructuring. Counsel who understands both capital markets and insolvency can help the fund analyze the full distribution of outcomes rather than only the preferred case.
Ye's public profile also shows experience with government-guided and state-owned investment platforms. These investors may have additional constraints relating to valuation, decision-making, state-asset procedures and accountability. A distressed portfolio-company decision can therefore require careful documentation of why additional capital, an asset sale or a write-off is reasonable.
For foreign investors, the same practice mix is useful where an offshore fund or strategic investor participates in a Chinese life-sciences company alongside domestic funds. The shareholder agreement may contain liquidation preferences, repurchase rights, board vetoes and information rights. Chinese corporate and insolvency law determine how these rights operate when the company is under financial stress.
Capability
